慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响*

doi:10.3969/j.issn.1672-5069.2021.06.011

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMCs)半乳糖凝集素-3(galectin-3)表达水平对干扰素治疗应答的影响。方法 2016年12月～2019年12月我院收治的CHB患者106例,CHB患者均给予聚乙二醇干扰素α-2a治疗48周,随访24周。分离PBMCs,采用PCR和Western blot法检测PBMCs Galectin-3表达水平。结果在治疗24 w,本组CHB患者应答27例(22.6%),在治疗48 w,应答44例(67.0%);入组时,24 w应答组血清AST、ALT和HBV DNA水平【分别为(122.8±98.2)U/L、(108.1±51.1)U/L和(6.3±0.6)lg copies/ml】,与48 w应答组【分别为(124.2±94.7)U/L、(113.1±47.3)U/L和(6.5±0.8)lg copies/ml】或与未应答组【分别为(121.9±97.4)U/L、(96.1±56.4)U/L和(6.8±0.9)lg copies/ml】比,差异无显著性统计学意义(P>0.05);治疗24 w应答组外周血单个核细胞Galectin-3 mRNA相对水平为(3.0±0.5),蛋白相对表达量为(1.4±0.2),均显著高于治疗48 w应答组【分别为(1.8±0.4)和(0.9±0.1),P<0.05】或未应答组【分别为(1.1±0.2)和(0.8±0.1),P<0.05】。结论外周血单个核细胞Galectin-3水平与接受α-干扰素治疗的CHB患者应答密切相关,可以根据检测的结果预判治疗效果,值得临床进一步验证。

关键词: 慢性乙型肝炎, 干扰素-α, 外周血单个核细胞, Galectin-3, 应答

Abstract: Objective The aim of this study was to investigate the corrlation of peripheral blood mononuclear cell (PBMC) galectin-3 levels in patients with chronic hepatitis B (CHB) receiving interferon-α therapy. Methods 106 patients with CHB were enrolled in our hospital for treatment between December 2016 and December 2019, and all patients with CHB were treated with peginterferon α-2a (peg-IFN-α-2a) for 48 weeks and followed-up for 24 weeks. The peripheral blood mononuclear cells were isolated, and relative galectin-3 levels were detected by PCR and Western bloting. Results At the end of 24 week treatment, 27 patients (22.6%)got complete response, and at the end of 48 week treatment, 44 patients (67.0%) responded to anti-viral therapy; at presentation, serum AST, ALT and HBV DNA levels in patients responded at 24 week were(122.8±98.2)U/L,(108.1±51.1)U/L and (6.3±0.6)lg copies/ml, not significantly different compared to (124.2±94.7)U/L, (113.1±47.3)U/L and (6.5±0.8)lg copies/ml in patients responded at 48 week, and also not significantly different compared to (121.9±97.4)U/L, (96.1±56.4)U/L and (6.8±0.9)lg copies/ml in non-responders (P>0.05); the PBMC galectin-3 mRNA level was (3.0±0.5) and its protein level was (1.4±0.2) in patients responded at 24 week, significantly higher than [(1.8±0.4) and (0.9±0.1), respectively, P<0.05] in patients responded at 48 week or [(1.1±0.2) and (0.8±0.1), respectively, P<0.05] in non-responders. Conclusion The galectin-3 levels in peripheral blood mononuclear cells is closely related to the response to anti-viral treatment in patients with CHB, and it might predict the outcome of patients with CHB after interferon-α therapy.

Key words: Hepatitis B, Interferon-α, Peripheral blood mononuclear cells, Galectin-3, Response

许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.

Xu Zhengheng, Huang Yong, Ke Haixia, et al. Correlation of peripheral blood mononuclear cell galectin-3 levels in patients with chronic hepatitis B receiving interferon-α therapy[J]. Journal of Practical Hepatology, 2021, 24(6): 811-814.

参考文献

[1] Stasi C, Silvestri C, Voller F. Emerging trends in epidemiology of hepatitis B virus infection. J Clin Transl Hepatol, 2017, 5(3): 272-276.
[2] Boglione L, Cariti G, Ghisetti V, et al. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.J Med Virol, 2018, 90(6):1047-1052.
[3] 白一春,邓霁红,梅小平.影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析.实用肝脏病杂志,2019,22(4):490-493.
[4] Frangogiannis NG. Galectin-3 in the fibrotic response: Cellular targets and molecular mechanisms. Int J Cardiol, 2018, 258:226-227.
[5] Stojanovic B, Milovanovic J, Arsenijevic A, et al. Galectin-3deficiency facilitates TNF-α-dependent hepatocyte death and liver inflammation in MCMV infection. Front Microbiol, 2019, 10:185.
[6] Ulu M, Alacacioglu A, Yuksel E, et al. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol, 2015, 21(1):47-50.
[7] Wang J, Li C, Fu J,et al. Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B. Scand J Immunol, 2019, 89(5):e12755.
[8] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):389-400.
[9] 袁春晖,李春雨,李红丽,等. IL28B基因多态性对聚乙二醇干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效的影响.实用肝脏病杂志,2019,22(2):184-187.
[10] Churlaud G, Abbara C, Vinot PA, et al. Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2. J Allergy Clin Immunol, 2018, 142(4):1344-1346.
[11] Palacz M, Tremellen K. High body Mass index is associated with an expansion of endometrial T regulatory cell and macrophage populations. J Reprod Immunol, 2018, 12(9):36-39.
[12] 张海洋,宋展,王鑫,等.半乳凝素3对结直肠癌细胞生物学行为的影响.中华实验外科杂志,2019,36(5):855-857.
[13] Nangia-Makker P, Hogan V, Raz A. Galectin-3 and cancer stemness. Glycobiology, 2018, 28(4):172-181.
[14] Song M, Pan Q, Yang J, et al. Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma. Br J Cancer, 2020, 123(10):1521-1534.
[15] Liu T, Liu D, Liu R, et al. Discovering potential serological biomarker for chronic hepatitis B virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis. Sci Rep, 2017, 7:38918.
[16] Çavuş B, Akyuz F, Iliaz R, et al. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma. Exp Oncol, 2020, 42(3):208-214.
[17] Wang M, Tian F, Ying W, et al. Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of galectin-3 in hepatocellular carcinoma. Rep Dis, 2017, 7(1):5189.
[18] Majidinia M, Aghazadeh J, Jahanban-Esfahlani R, et al. The roles of Wnt/β-catenin pathway in tissue development and regenerative medicine. J Cell Physiol, 2018, 233(8):5598-5612.
[19] Uluca Ü, Şen V, Ece A, et al. Serum galectin-3 levels in children with chronic hepatitis B infection and inactive hepatitis B carriers. Med Sci Monit, 2015, 21:1376-1380.
[20] 李宜,余龙,吴晓玲.聚乙二醇干扰素α-2a对慢性乙型肝炎患者外周血单个核细胞Galectin-3表达的影响.中华肝脏病杂志,2014,22(5):336-339.

慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*

Correlation of peripheral blood mononuclear cell galectin-3 levels in patients with chronic hepatitis B receiving interferon-α therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄飞虎, 薛建亚, 朱咏梅, 余姣, 王丽艳, 鲁琼. 应用索磷布韦/维帕他韦治疗门诊和住院筛查的丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 819-822.
[2]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[3]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[4]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[5]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[6]	周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.
[7]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[8]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[9]	吴慧, 宋波, 吕承秀, 田文君, 牛家峰. 慢性乙型肝炎患者血清内质网应激指标变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(4): 484-487.
[10]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[11]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[12]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[13]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[14]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[15]	张思薇, 孔银, 刘天府, 刘元元, 麻爱娣, 李永芳, 李娟, 张岭漪. 肝脏硬度检测联合吲哚菁绿滞留率测定对血清转氨酶正常或轻度升高的慢性乙型肝炎患者肝组织学病变进展的预测价值[J]. 实用肝脏病杂志, 2021, 24(2): 184-187.